Xinzhi Li

Dr. Xinzhi Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
XZXin Zhang
Xin Zhang
JRJennifer A. Ritonja
Jennifer A. Ritonja
NZNa Zhou
Na Zhou
BCBingshu E. Chen
Bingshu E. Chen
XLXinzhi Li
Xinzhi Li
Background: Current evidence might support the use of omega‐3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose‐response relationship remains unclear. Methods and Results: This study included randomized controlled trials published before May 7, 2021, that involved participants aged ≥18 years, and examined an association between omega‐3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, or both) and BP. A random‐effects 1‐stage cubic spline regression model was used to predict the average dose‐response association between daily omega‐3 fatty acid intake and changes in BP. We also conducted stratified analyses to examine differences by prespecified subgroups. Seventy‐one trials were included, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A nonlinear association was found overall or in most subgroups, depicted as J‐shaped dose‐response curves. The optimal intake in both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, −2.61 [95% CI, −3.57 to −1.65]; diastolic BP, −1.64 [95% CI, −2.29 to −0.99]) and 3 g/d (systolic BP, −2.61 [95% CI, −3.52 to −1.69]; diastolic BP, −1.80 [95% CI, −2.38 to −1.23]). Subgroup studies revealed stronger and approximately linear dose‐response relations among hypertensive, hyperlipidemic, and older populations. Conclusions: This dose‐response meta‐analysis demonstrates that the optimal combined intake of omega‐3 fatty acids for BP lowering is likely between 2 g/d and 3 g/d. Doses of omega‐3 fatty acid intake above the recommended 3 g/d may be associated with additional benefits in lowering BP among groups at high risk for cardiovascular diseases.

6 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
TWTianjiao Wang
Tianjiao Wang
XZXin Zhang
Xin Zhang
NZNa Zhou
Na Zhou
YSYuxuan Shen
Yuxuan Shen
BLBiao Li
Biao Li
XLXinzhi Li
Xinzhi Li
Background: Previous results provide supportive but not conclusive evidence for the use of omega‐3 fatty acids to reduce blood lipids and prevent events of atherosclerotic cardiovascular disease, but the strength and shape of dose–response relationships remain elusive. Methods and Results: This study included 90 randomized controlled trials, reported an overall sample size of 72 598 participants, and examined the association between omega‐3 fatty acid (docosahexaenoic acid, eicosapentaenoic acid, or both) intake and blood lipid changes. Random‐effects 1‐stage cubic spline regression models were used to study the mean dose–response association between daily omega‐3 fatty acid intake and changes in blood lipids. Nonlinear associations were found in general and in most subgroups, depicted as J‐shaped dose–response curves for low‐/high‐density lipoprotein cholesterol. However, we found evidence of an approximately linear dose–response relationship for triglyceride and non‐high‐density lipoprotein cholesterol among the general population and more evidently in populations with hyperlipidemia and overweight/obesity who were given medium to high doses (>2 g/d). Conclusions: This dose–response meta‐analysis demonstrates that combined intake of omega‐3 fatty acids near linearly lowers triglyceride and non‐high‐density lipoprotein cholesterol. Triglyceride‐lowering effects might provide supportive evidence for omega‐3 fatty acid intake to prevent cardiovascular events.

22 June 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XLXinzhi Li
Xinzhi Li
ZMZhongyuan Ma
Zhongyuan Ma
Yi Zhun ZhuYi Zhun Zhu
Yi Zhun Zhu
Perivascular adipose tissue (PVAT) is a unique fat depot with local and systemic impacts. PVATs are anatomically, developmentally, and functionally different from classical adipose tissues and they are also different from each other. PVAT adipocytes originate from different progenitors and precursors. They can produce and secrete a wide range of autocrine and paracrine factors, many of which are vasoactive modulators. In the context of obesity-associated low-grade inflammation, these phenotypic and functional differences become more evident. In this review, we focus on the recent findings of PVAT’s heterogeneity by comparing commonly studied adipose tissues around the thoracic aorta (tPVAT), abdominal aorta (aPVAT), and mesenteric artery (mPVAT). Distinct origins and developmental trajectory of PVAT adipocyte potentially contribute to regional heterogeneity. Regional differences also exist in ways how PVAT communicates with its neighboring vasculature by producing specific adipokines, vascular tone regulators, and extracellular vesicles in a given microenvironment. These insights may inspire new therapeutic strategies targeting the PVAT.

5 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HWHaobin Wei
Haobin Wei
ZCZhang Chen
Zhang Chen
WLWenjie Lai
Wenjie Lai
WWWenxian Wang
Wenxian Wang
XBXiqing Bian
Xiqing Bian
XLXinzhi Li
Xinzhi Li
Background: Portulaca oleracea L. (PO) is an edible plant with a long medicinal history in traditional Chinese medicine for various inflammatory diseases, including skin disorders such as atopic dermatitis (AD). However, the anti-inflammatory effects and AD-alleviating mechanisms of PO remain unclear.Methods: PO aqueous extract was prepared from a water-soluble portion and then mixed with carbomer to obtain a hydrogel, which provided stable drug permeation and absorption in mouse skin. Amantadine acetate was identified as an abundant ingredient and further predicted to be a Janus kinase 1 (JAK1) inhibitor via molecular binding simulation. Mice with AD, established by repeated sensitization with 2,4-dinitrochlorobenzene (DNCB), were topically treated with PO hydrogel. Aurantiamide acetate was applied to HaCaT keratinocytes prior to inflammatory challenge in the presence or absence of JAK1-siRNA. Transcriptional and translational gene expressions associated with cutaneous inflammation or skin barriers were assessed by qPCR and Western blotting, respectively. Enzyme-linked immunosorbent assays were performed to detect immunoglobulin E and proinflammatory factors in skin tissue or serum. The phosphorylation of JAK1, signal transducer and activator of transcription (STAT)3, and STAT6 in keratinocytes and skin were analyzed by Western blotting.Results: In DNCB-sensitized mice, the PO hydrogel ameliorated skin lesions, lowered symptom scores, and reduced epidermal thickness by suppressing proinflammatory factor generation, oxidative stress, and the expression of CD4+. The PO hydrogel promoted the expression of caspase-14 and filaggrin, thereby helping restore skin barrier function in AD. The PO hydrogel and/or aurantiamide acetate inhibited the enzymatic activity of JAK1 and downstream (STAT)3/STAT6 signaling pathways in vitro and in vivo.Conclusion: PO significantly ameliorated skin lesions and restored epidermal barrier function in AD mice. This was achieved by suppressing JAK1 enzymatic activity and JAK1-mediated STAT signaling pathways.

2 August 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YLYujuan Li
Yujuan Li
ZCZhang Chen
Zhang Chen
YXYing Xiao
Ying Xiao
XLXinzhi Li
Xinzhi Li
Perivascular adipose tissue (PVAT) is a unique fat depot surrounding blood vessels and plays a vital role in the progression of vascular remodeling and dysfunction. PVAT exhibits remarkable differences in structure, phenotype, origin, and secretome across anatomical locations. The proximity of PVAT to neighboring vascular beds favors a niche for bidirectional communication between adipocytes and vascular smooth muscle cells, endothelial cells, and immune cells. In this review, we update our understanding of PVAT’s regional differences and provide a comprehensive exploration of how these differences impact cross-talks between PVAT and the vascular wall. Different PVAT depots show different degrees of vasoprotective function and resilience to pathological changes such as obesity and vasculopathies, shaping multifaceted interactions between PVAT depots and adjacent vasculatures. The depot-specific resilience may lead to innovative strategies to manage cardiometabolic disorders.

27 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LZLinsheng Zeng
Linsheng Zeng
WLWenjie Lai
Wenjie Lai
YLYueyang Li
Yueyang Li
MYMeiling Yang
Meiling Yang
JLJing Liang
Jing Liang
GTGuangdong Tong
Guangdong Tong
Chronic chikungunya arthritis (CCA) is a major long-term sequela of Chikungunya virus (CHIKV) infection. Its pathogenesis involves persistent viral reservoirs in joint tissues, metabolic reprogramming of myeloid cells, dysregulated Treg/Th17 immunity, and autoimmune-like tissue injury. This review integrates recent advances in virology, immunometabolism, and clinical pathology to propose a four-stage pathological cascade: “viral persistence”, “myeloid metabolic dysregulation”, “Treg/Th17 imbalance”, and “autoimmunity-like injury”. Key cytokine networks and molecular interactions at each stage are summarized. Based on this model, we outline stage-specific therapeutic strategies, including antiviral agents targeting Mxra8 or nsP1 (Stage I), metabolic modulators such as HIF-1α inhibitors and IL-1β blockade (Stage II), immune-restorative therapies such as low-dose IL-2 and CTLA-4-Ig (Stage III), and anti-inflammatory biologics or DMARDs for RA-like pathology (Stage IV). This framework provides a mechanistic basis for precision intervention and supports the development of biomarkers and clinical trial designs for CCA.